Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Molecular Psychiatry
|
July 19, 2025
Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2/D3 antagonism, D2/D3 partial agonism and placebo
Martin Osugo, Uzma Zahid, Pierluigi Selvaggi, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|
January 12, 2021
The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis
Oliver D Howes, Thomas Whitehurst, Ekaterina Shatalina, et al.
Biological Psychiatry
|
June 17, 2023
Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A
Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 7, 2025
Antipsychotics cause reversible structural brain changes within one week
Pierluigi Selvaggi, Martin Osugo, Uzma Zahid, et al.
Nature Communications
|
February 21, 2025
Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
Martin Osugo, Matthew B Wall, Pierluigi Selvaggi, et al.
JAMA Psychiatry
|
December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms
Martin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Translational Psychiatry
|
March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging study
Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
February 2, 2026
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography study
Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
The British Journal of Psychiatry : the Journal of Mental Science
|
July 23, 2025
The effects of dopamine receptor antagonist and partial agonist antipsychotics on the glutamatergic system: double-blind, randomised, placebo-controlled <sup>1</sup>H-MRS cross-over study in healthy volunteers
Uzma Zahid, Martin Osugo, Pierluigi Selvaggi, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
March 21, 2026
Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach
Claudio Agnorelli, Joseph Peill, Gabriela Sawicka, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Molecular Psychiatry
|
July 19, 2025
Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2/D3 antagonism, D2/D3 partial agonism and placebo
Martin Osugo, Uzma Zahid, Pierluigi Selvaggi, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|
January 12, 2021
The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis
Oliver D Howes, Thomas Whitehurst, Ekaterina Shatalina, et al.
Biological Psychiatry
|
June 17, 2023
Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A
Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 7, 2025
Antipsychotics cause reversible structural brain changes within one week
Pierluigi Selvaggi, Martin Osugo, Uzma Zahid, et al.
Nature Communications
|
February 21, 2025
Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
Martin Osugo, Matthew B Wall, Pierluigi Selvaggi, et al.
JAMA Psychiatry
|
December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms
Martin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Translational Psychiatry
|
March 2, 2025
The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging study
Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
February 2, 2026
Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [<sup>11</sup>C]UCB-J positron emission tomography study
Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, et al.
The British Journal of Psychiatry : the Journal of Mental Science
|
July 23, 2025
The effects of dopamine receptor antagonist and partial agonist antipsychotics on the glutamatergic system: double-blind, randomised, placebo-controlled <sup>1</sup>H-MRS cross-over study in healthy volunteers
Uzma Zahid, Martin Osugo, Pierluigi Selvaggi, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
March 21, 2026
Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach
Claudio Agnorelli, Joseph Peill, Gabriela Sawicka, et al.
Page
of 3